Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-guided therapy in ES-SCLC
NCT07106528Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 100 months. Planned start Aug 2025; status: not yet recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07106528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106528.